Panacea Biotec Q2 Results 2026: PAT ₹12 Cr (turned profitable)
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹190Cr
- +34.4% YoY
- −5% QoQ
- Net profit
- ₹12Cr
- Turned profitable YoY
- +441.4% QoQ
- Margin
- 8.2%
- +20.8 pp YoY
- +5.4 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Panacea Biotec Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Quarter Revenue Figures (Consolidated):. EBITDA for the quarter ended September 30, 2026:.
From Panacea Biotec Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.
How did Panacea Biotec's revenue grow in the September 2026 quarter?
- Quarter Revenue Figures (Consolidated):
- September 30, 2026: ₹18,967 Lakh
- September 30, 2025: ₹14,113 Lakh
- Year-on-year increase: ₹4,854 Lakh (~34.4% growth)
- Segment Revenue for the Quarter:
2 more points from Panacea Biotec Ltd's call on revenue
Create a free account to keep reading this call
What happened to Panacea Biotec's margins in Q2 FY27?
EBITDA for the quarter ended September 30, 2026:
Locked: what Panacea Biotec Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Panacea Biotec planning?
- The Group is using surplus funds from the sale of pharmaceutical brands (India & Nepal, March 2022) to:
- Strengthen working capital
- Set up new facilities for enhancing vaccine drug substance manufacturing capacity
- Scale up nutrition and pharmaceutical formulations business
- Pursue other business opportunities
- Capital work-in-progress standalone: ₹9,402 lakh (Sep 30, 2026), consolidated: ₹10,844 lakh
- Property, plant & equipment: Standalone ₹34,114 lakh; Consolidated ₹53,775 lakh (Sep 30, 2026)
- Capital expenditure payments during half-year ended Sep 30, 2026:
- Standalone: ₹1,194 lakh
- Consolidated: ₹1,378 lakh
- Investments made during half-year ended Sep 30, 2026:
2 more points from Panacea Biotec Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Panacea Biotec raising money or cutting debt?
The standalone cash flow statement (Page 6) shows proceeds from current borrowings of ₹6,026 lakh for the…
Locked: what Panacea Biotec Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Panacea Biotec's order book?
See what Panacea Biotec Ltd said on order book & pipeline — free account, 30 seconds.
Panacea Biotec Ltd — Quarterly revenue & net profit
Panacea Biotec Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 190 | 141 | +34.4% | 200 | -5% |
| Operating profit (EBITDA) | 16 | -18 | — | 6 | +173.4% |
| Operating margin | 8.2% | -12.6% | +20.8 pp | 2.8% | +5.4 pp |
| Profit before tax | 17 | -19 | — | 4 | +375.9% |
| Net profit (PAT) | 12 | -14 | — | 2 | +441.4% |
| EPS (₹) | 1.90 | -2.27 | — | 0.38 | +400% |
Source: Panacea Biotec Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹190 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
- Alpa Laboratorie (Q2 FY27)
Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aarey Drugs (Q2 FY27)
Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs . Key results statement takeaways from Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Panacea Biotec Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Panacea Biotec Ltd Q2 FY27 results?
Quarter Revenue Figures (Consolidated):. EBITDA for the quarter ended September 30, 2026:.
What is Panacea Biotec Ltd share price analysis?
Panacea Biotec Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,159 Cr. Investors should review the full earnings analysis for detailed insights.
Is Panacea Biotec Ltd planning capital expenditure?
The Group is using surplus funds from the sale of pharmaceutical brands (India & Nepal, March 2022) to:.
Keep Panacea Biotec Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
